Hemispherx Biopharma (HEB) Filing a New Drug Application in Argentina for Ampligen® to Treat Chronic Fatigue Syndrome  
7/18/2012 9:19:19 AM

PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT's Orphan Drug regulations.